Suppr超能文献

结直肠癌肝转移患者存在 RAS 基因突变时无需进行解剖性肝切除术。

Anatomic Resection Is Not Required for Colorectal Liver Metastases with RAS Mutation.

机构信息

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX, 77030, USA.

出版信息

J Gastrointest Surg. 2020 May;24(5):1033-1039. doi: 10.1007/s11605-019-04299-6. Epub 2020 Mar 10.

Abstract

BACKGROUND

Non-anatomic resection (NAR) has emerged as a safe and effective technique for resection of colorectal liver metastases (CRLM). More recently, RAS mutation has been identified as an important indicator of aggressive disease, which may require anatomic resection (AR). In this retrospective study, we compared the long-term outcomes of AR versus NAR in CRLM patients with and without RAS mutations.

METHODS

Patients with known RAS mutation status who underwent AR or NAR for CRLM between 2006 and 2016 were included. Differences in baseline characteristics were adjusted using 1:1 propensity score matching, including the most important factors that contributed to the decision to use the resection technique. Overall survival (OS), recurrence-free survival (RFS), and liver-specific recurrence-free survival (L-RFS) were compared between cohorts.

RESULTS

Among 622 total patients, 338 (54%) underwent AR and 284 (46%) NAR. There was no difference in OS or L-RFS between the AR and NAR groups, regardless of mutation status. There was increased RFS in the RAS WT patients with NAR (P = 0.034), but no difference in RFS in the whole cohort or RAS mutant group. After propensity score matching, 360 patients were analyzed, and no differences in OS, RFS, or L-RFS rates were seen between any groups. There was also no difference in margin recurrence.

CONCLUSIONS

Similar outcomes can be achieved with both AR and NAR, regardless of RAS mutation status. These data do not support a universal requirement for AR in RAS mutant CRLM when not necessary to achieve an R0 resection.

摘要

背景

非解剖性切除术(NAR)已成为结直肠癌肝转移(CRLM)切除的安全有效技术。最近,RAS 突变已被确定为侵袭性疾病的重要指标,可能需要解剖性切除术(AR)。在这项回顾性研究中,我们比较了 RAS 突变阳性和阴性的 CRLM 患者接受 AR 与 NAR 的长期结果。

方法

纳入 2006 年至 2016 年间接受 AR 或 NAR 治疗的已知 RAS 突变状态的 CRLM 患者。使用 1:1 倾向评分匹配调整基线特征差异,包括导致选择切除技术的最重要因素。比较两组之间的总生存期(OS)、无复发生存期(RFS)和肝脏特异性无复发生存期(L-RFS)。

结果

在 622 例患者中,338 例(54%)接受 AR,284 例(46%)接受 NAR。无论突变状态如何,AR 和 NAR 组之间的 OS 或 L-RFS 均无差异。在 RAS WT 患者中,NAR 组的 RFS 增加(P=0.034),但在全队列或 RAS 突变组中 RFS 无差异。在进行倾向评分匹配后,对 360 例患者进行分析,各组间 OS、RFS 或 L-RFS 率均无差异。切缘复发率也无差异。

结论

无论 RAS 突变状态如何,AR 和 NAR 均可获得相似的结果。这些数据不支持在没有必要实现 R0 切除的情况下,对 RAS 突变的 CRLM 普遍要求进行 AR。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验